Trial Profile
A Phase 2 Open-Label, Randomized, Multi-Center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Leuprorelin; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacodynamics
- Acronyms Neo-Abi trial
- Sponsors Janssen Research & Development
- 13 Feb 2021 Results of pooled analysis of post-RP outcomes from four clinical trials (NCT00298155; NCT00924469; NCT01547299; NCT02268175) presented at the 2021 Genitourinary Cancers Symposium
- 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
- 05 May 2013 Primary endpoint 'Testosterone-levels' has been met.